Clinical Trial Update: CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CS-7017 in combination with erlotinib in stage IIIb/IV non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CS-7017
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2020-07-31